Godavari Drugs Ltd. · CashKonnect

About

Godavari Drugs Limited manufactures and sells active pharmaceutical ingredients (APIs), drug intermediaries, and fine chemicals in India. The company offers APIs, including ciprofloxacin HCl, ciprofloxacin lactate, ciprofloxacin betaine, mefenamic acid, enrofloxacin, and elthambutoal HCI; and intermediaries, such as A D lactone for spironolactone and 6 mercaptopurine for azathioprine. It also provides loan licenses and contract manufacturing services for APIs and drug intermediates. The company serves the life science industry. Godavari Drugs Limited was incorporated in 1987 and is based in Secunderabad, India.

Quarterly Results

Rs. Crores · hover row for definition

Metric	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023
Sales	27.96	33.16	22.18	26.65	23.81	25.50	29.55	26.09	32.21	38.64	43.11	39.54	35.42
Expenses	25.44	30.22	19.71	24.65	20.91	22.39	26.97	23.19	28.98	34.17	39.59	36.47	33.17
Operating Profit	2.52	2.94	2.47	2.00	2.90	3.11	2.58	2.90	3.23	4.47	3.52	3.07	2.25
OPM %	9.01	8.87	11.14	7.50	12.18	12.20	8.73	11.12	10.03	11.57	8.17	7.76	6.35
Other Income	0.15	0.25	0.27	0.64	0.01	0.11	0.10	0.01	0.77	0.08	-0.01	0.00	0.45
Depreciation	0.59	0.61	0.61	0.60	0.60	0.67	0.64	0.58	0.55	0.53	0.50	0.49	0.47
Interest	0.90	0.96	1.11	0.91	1.00	1.11	1.11	1.08	1.44	1.23	1.27	1.30	1.11
Profit before tax	1.18	1.62	1.02	1.13	1.31	1.44	0.93	1.25	2.01	2.79	1.74	1.28	1.12
Tax %	5.93	20.37	25.49	10.62	19.85	38.19	16.13	12.80	18.91	4.66	29.89	32.81	27.68
Net Profit	1.11	1.29	0.76	1.00	1.04	0.89	0.77	1.09	1.63	2.66	1.22	0.86	0.81
EPS in Rs	1.10	1.27	1.01	1.33	1.38	1.18	1.02	1.45	2.16	3.53	1.62	1.14	1.08

Profit & Loss

Annual · Rs. Crores

Metric	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015
Sales	106.00	113.00	157.00	160.00	161.00	123.00	96.00	84.00	64.00	76.00	71.00	55.00
Expenses	95.00	102.00	143.00	150.00	150.00	113.00	90.00	78.00	60.00	70.00	67.00	49.00
Operating Profit	10.00	12.00	13.00	10.00	11.00	10.00	6.00	5.00	4.00	5.00	4.00	6.00
OPM %	10.00	10.00	8.00	6.00	7.00	8.00	6.00	7.00	6.00	7.00	6.00	11.00
Other Income	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	1.00	1.00	0.00	0.00
Interest	4.00	5.00	5.00	4.00	3.00	3.00	3.00	3.00	2.00	3.00	2.00	1.00
Depreciation	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Profit before tax	5.00	6.00	7.00	5.00	7.00	6.00	2.00	2.00	1.00	3.00	2.00	5.00
Tax %	19.00	22.00	20.00	23.00	25.00	28.00	13.00	31.00	37.00	33.00	38.00	23.00
Net Profit	4.00	4.00	6.00	4.00	5.00	4.00	2.00	1.00	1.00	2.00	1.00	4.00
EPS in Rs	4.04	5.82	7.37	5.03	6.97	5.48	2.66	1.61	1.10	2.40	1.79	4.85
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Balance Sheet

Annual · Rs. Crores — latest first

Metric	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015
Equity Capital	10.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00
Reserves	66.00	36.00	31.00	26.00	22.00	17.00	13.00	11.00	10.00	9.00	7.00	6.00
Borrowings	82.00	64.00	58.00	36.00	23.00	30.00	28.00	22.00	19.00	16.00	16.00	8.00
Other Liabilities	43.00	35.00	38.00	52.00	49.00	36.00	36.00	33.00	27.00	24.00	21.00	13.00
Total Liabilities	200.00	143.00	135.00	121.00	101.00	91.00	84.00	74.00	63.00	56.00	51.00	35.00
Fixed Assets	30.00	33.00	27.00	25.00	26.00	22.00	14.00	15.00	15.00	13.00	9.00	7.00
CWIP	57.00	30.00	18.00	9.00	0.00	1.00	9.00	2.00	1.00	0.00	1.00	0.00
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	114.00	81.00	90.00	87.00	75.00	68.00	61.00	57.00	47.00	43.00	41.00	27.00
Total Assets	200.00	143.00	135.00	121.00	101.00	91.00	84.00	74.00	63.00	56.00	51.00	35.00

Cash Flows

Annual · Rs. Crores — latest first

Metric	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015
Cash from Operating Activity	1.00	11.00	18.00	13.00	11.00	1.00	6.00	4.00	4.00	5.00	-5.00	-6.00
Cash from Investing Activity	-26.00	-20.00	-13.00	-9.00	-5.00	-1.00	-7.00	-2.00	-3.00	-3.00	-2.00	0.00
Cash from Financing Activity	37.00	8.00	-6.00	-4.00	-6.00	0.00	0.00	-1.00	0.00	-2.00	7.00	6.00
Net Cash Flow	12.00	0.00	0.00	1.00	1.00	0.00	0.00	0.00	1.00	0.00	0.00	0.00
Free Cash Flow	-26.00	-9.00	5.00	4.00	6.00	0.00	-1.00	1.00	0.00	1.00	-7.00	-6.00
CFO/OP %	19.00	105.00	146.00	143.00	110.00	26.00	108.00	73.00	109.00	108.00	-101.00	-101.00

Ratios

Annual · Days / % — latest first

Metric	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015
Debtor Days	150.00	136.00	138.00	132.00	126.00	134.00	137.00	148.00	152.00	117.00	126.00	87.00
Inventory Days	217.00	125.00	62.00	57.00	28.00	55.00	84.00	93.00	100.00	70.00	67.00	84.00
Days Payable	163.00	128.00	96.00	132.00	121.00	112.00	144.00	171.00	171.00	124.00	108.00	79.00
Cash Conversion Cycle	204.00	133.00	105.00	58.00	33.00	78.00	78.00	70.00	81.00	63.00	85.00	92.00
Working Capital Days	42.00	11.00	9.00	23.00	32.00	46.00	31.00	38.00	47.00	40.00	44.00	63.00
ROCE %	7.00	10.00	14.00	14.00	18.00	18.00	12.00	12.00	11.00	17.00	16.00	32.00

Shareholding Pattern

% holding — latest first

Holder	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Promoters	40.23	40.23	52.61	52.61	52.63	52.63	52.63	52.63	53.16	53.16	53.16	53.16
DIIs	2.74	2.47	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50
Public	57.04	57.31	46.89	46.90	46.87	46.87	46.87	46.87	46.34	46.34	46.35	46.33
No. of Shareholders	6,722	7,300	7,483	7,720	7,828	7,881	7,915	7,709	7,044	7,005	6,894	7,019